Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States

J Med Econ. 2013; 16(2):278-88

View abstract

Authors

Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.